Petter Olsson
- QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK studyBy Jadwiga A. Wedzicha, Marc Decramer, Petter Olsson, Hungta Chen, Robert Fogel and Donald BanerjiJadwiga A. Wedzicha1Centre for Respiratory Medicine, University College London, London, United KingdomMarc Decramer2Respiratory Division, University of Leuven, Leuven, BelgiumPetter Olsson3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE studyBy Kenneth R. Chapman, Eric D. Bateman, Petter Olsson, Hungta Chen, Donald Banerji and Robert FogelKenneth R. Chapman1Asthma and Airway Centre, University Health Network, University of Toronto, Ontario, CanadaEric D. Bateman2Department of Medicine, University of Cape Town, Cape Town, South AfricaPetter Olsson3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE studyBy Anthony D'Urzo, Donald A. Mahler, Petter Olsson, Hungta Chen, Robert Fogel and Donald BanerjiAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaDonald A. Mahler2Section of Pulmonary & Critical Care Medicine, Geisel School of Medicine, Dartmouth, NH,Petter Olsson3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.